Astellas Pharma (ALPMY) Stock Forecast & Price Target

Astellas Pharma
Bear Case

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

• The company recently missed its earnings per share expectations, reporting $0.35 in EPS for the quarter against a consensus estimate of $0.41, which may signal underlying operational challenges or cost pressures that could impact future profitability.
• Analyst sentiment has shifted negatively, with Zacks Research downgrading the stock from a "strong-buy" to a "hold" rating, and the company was added to the Zacks Rank #5 (Strong Sell) list in August 2026, reflecting a lack of confidence in its near-term earnings trajectory.
• Astellas Pharma Inc. recently halted an early-stage clinical trial for a KRAS G12D cancer treatment, which represents a setback in its oncology pipeline and could delay the introduction of new revenue-generating therapies in a key therapeutic area.
• The company faces potential regulatory and pricing risks as part of the expanding Most Favored Nation (MFN) agreements, which could pressure drug pricing and margins in the United States, a significant market for its pharmaceutical products.
• Short interest in the stock has been volatile, with a significant spike to 155,427 shares in September 2026, indicating that some market participants are betting against the stock's performance, which can create downward pressure on the share price.